CPT code 80280 represents a laboratory test that quantitatively measures vedolizumab level in a patient specimen. Vedolizumab is a gastrointestinal-selective monoclonal antibody targeting integrin alpha-4 beta-7 (LPAM1); measuring drug concentration informs therapeutic drug monitoring and can guide treatment decisions in inflammatory bowel disease management. Nationally, availability of validated quantitative assays and appropriate coding affect billing, clinical reporting, and access to therapeutic monitoring services.

Key payers addressed in typical commercial and public coverage environments include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage policies and payment for specialty immunoassays vary by payer and by clinical indication.

Readers will find a concise explanation of the clinical context for CPT code 80280, the service setting and typical laboratory workflow, and an outline of payer coverage landscape. The publication provides benchmark and policy-relevant content about coding and billing for vedolizumab quantitative assays, clinical indications for drug-level testing, and operational considerations for labs offering this service. Data not available in the input will be identified as such where relevant.